<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Written evidence submitted by Novartis (AMR0003)</title></head><body><div><p style="margin:0pt"><span style="font-family:'Century Gothic'; font-size:11pt">&#xa0;</span></p><p style="margin:5pt 0pt; text-align:center"><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Novartis</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> (AMR0003)</span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Focus on Antibiotics</span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">How has antimicrobial resistance developed in the past decade?</span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Multidrug-resistant (MDR) pathogens represent one of the greatest </span><span style="font-family:'Times New Roman'; font-size:11pt">challenges</span><span style="font-family:'Times New Roman'; font-size:11pt"> to human health</span><span style="font-family:'Times New Roman'; font-size:11pt">. Antibiotic resistance is</span><span style="font-family:'Times New Roman'; font-size:11pt"> now</span><span style="font-family:'Times New Roman'; font-size:11pt"> a linked global problem, with the dissemination of successful clones of MDR bacteria </span><span style="font-family:'Times New Roman'; font-size:11pt">often</span><span style="font-family:'Times New Roman'; font-size:11pt"> associated with the movement of people</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt">. The excessive and/or inappropriate use of antibiotics </span><span style="font-family:'Times New Roman'; font-size:11pt">is</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">a </span><span style="font-family:'Times New Roman'; font-size:11pt">major ca</span><span style="font-family:'Times New Roman'; font-size:11pt">usative factor for the local evolution of MDR bacteria that can be further exacerbated by horizontal gene transfer of resistance determinants between different bacterial species</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The last decade has seen the emergence of antimicrobial resistance </span><span style="font-family:'Times New Roman'; font-size:11pt">affecting entire classes of antibiotics including quinolones, t</span><span style="font-family:'Times New Roman'; font-size:11pt">etracyclines, glycopeptides, </span><span style="font-family:'Times New Roman'; font-size:11pt">macrolides</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt">β</span><span style="font-family:'Cambria Math'; font-size:11pt">‐</span><span style="font-family:'Times New Roman'; font-size:11pt">lactams including carbapenems</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">In the same time period </span><span style="font-family:'Times New Roman'; font-size:11pt">only </span><span style="font-family:'Times New Roman'; font-size:11pt">three new antibiotics were </span><span style="font-family:'Times New Roman'; font-size:11pt">successfully </span><span style="font-family:'Times New Roman'; font-size:11pt">introduced</span><span style="font-family:'Times New Roman'; font-size:11pt"> to</span><span style="font-family:'Times New Roman'; font-size:11pt"> market</span><span style="font-family:'Times New Roman'; font-size:11pt"> (linezolid, daptomycin a </span><span style="font-family:'Times New Roman'; font-size:11pt">ceftaroline)</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Of great concern is that for some MDR bacteria, no active antibiotic is available, with the fear that this problem will increase over time</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">, 3</span><span style="font-family:'Times New Roman'; font-size:11pt">. In the USA it is estimated that &gt; 15% of hea</span><span style="font-family:'Times New Roman'; font-size:11pt">l</span><span style="font-family:'Times New Roman'; font-size:11pt">thcare-ass</span><span style="font-family:'Times New Roman'; font-size:11pt">o</span><span style="font-family:'Times New Roman'; font-size:11pt">ciated infections are caused by MDR bacteria, while in Europe in 2007, it was estimated that ca. 25,000 patients died with an infection caused by and infection due to MDR </span><span style="font-family:'Times New Roman'; font-size:11pt">bacteria</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What are the gaps in our knowledge about antimicrobial resistance?</span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">H</span><span style="font-family:'Times New Roman'; font-size:11pt">os</span><span style="font-family:'Times New Roman'; font-size:11pt">pit</span><span style="font-family:'Times New Roman'; font-size:11pt">al based reporting of resistant</span><span style="font-family:'Times New Roman'; font-size:11pt"> infections has</span><span style="font-family:'Times New Roman'; font-size:11pt"> improved </span><span style="font-family:'Times New Roman'; font-size:11pt">markedly</span><span style="font-family:'Times New Roman'; font-size:11pt"> over the last decade</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">However, such reporting is frequently limited to a small number of pathogens (e.g. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Staphylococcus aureus, E.coli </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> glycopeptide-</span><span style="font-family:'Times New Roman'; font-size:11pt">resistant enterococci) and </span><span style="font-family:'Times New Roman'; font-size:11pt">indications (e.g. bacteraemia) as is exemplified by the mandatory surveillance program in England</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">4</span><span style="font-family:'Times New Roman'; font-size:11pt">. Information </span><span style="font-family:'Times New Roman'; font-size:11pt">relating to complex</span><span style="font-family:'Times New Roman'; font-size:11pt"> infections associated with a significant risk of antibiotic resistance, </span><span style="font-family:'Times New Roman'; font-size:11pt">(e.g. </span><span style="font-family:'Times New Roman'; font-size:11pt">implant-associated infections</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">is</span><span style="font-family:'Times New Roman'; font-size:11pt"> not generall</span><span style="font-family:'Times New Roman'; font-size:11pt">y collected.</span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">In the wider community </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">picture of in</span><span style="font-family:'Times New Roman'; font-size:11pt">cidence, prevalence, mortality </span><span style="font-family:'Times New Roman'; font-size:11pt">and cost of resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> remains incomplete</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">E</span><span style="font-family:'Times New Roman'; font-size:11pt">nhanced surveillance </span><span style="font-family:'Times New Roman'; font-size:11pt">outside the</span><span style="font-family:'Times New Roman'; font-size:11pt"> healthcare setting </span><span style="font-family:'Times New Roman'; font-size:11pt">will</span><span style="font-family:'Times New Roman'; font-size:11pt"> also </span><span style="font-family:'Times New Roman'; font-size:11pt">be </span><span style="font-family:'Times New Roman'; font-size:11pt">essential if we are to </span><span style="font-family:'Times New Roman'; font-size:11pt">measure and </span><span style="font-family:'Times New Roman'; font-size:11pt">understand </span><span style="font-family:'Times New Roman'; font-size:11pt">the impact</span><span style="font-family:'Times New Roman'; font-size:11pt"> of widespread antibiotic use in domestic, agricultural and industrial settings (e.g. sewage treatment). </span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">3. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">If not, how could this be</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">rectified?</span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">F</span><span style="font-family:'Times New Roman'; font-size:11pt">or pharmaceutical companies</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">the development of antibiotics does not represent a</span><span style="font-family:'Times New Roman'; font-size:11pt">n</span><span style="font-family:'Times New Roman'; font-size:11pt"> attractive commercial</span><span style="font-family:'Times New Roman'; font-size:11pt"> proposition</span><span style="font-family:'Times New Roman'; font-size:11pt"> when compared to new chemical entities in other areas of medicine (e.g. cardiology, respiratory medici</span><span style="font-family:'Times New Roman'; font-size:11pt">ne, rheumatology</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> cancer,</span><span style="font-family:'Times New Roman'; font-size:11pt"> chronic diseases</span><span style="font-family:'Times New Roman'; font-size:11pt">). </span><span style="font-family:'Times New Roman'; font-size:11pt">New approaches </span><span style="font-family:'Times New Roman'; font-size:11pt">and incentives </span><span style="font-family:'Times New Roman'; font-size:11pt">are required </span><span style="font-family:'Times New Roman'; font-size:11pt">to </span><span style="font-family:'Times New Roman'; font-size:11pt">ensure continued </span><span style="font-family:'Times New Roman'; font-size:11pt">industry commitment to the </span><span style="font-family:'Times New Roman'; font-size:11pt">development </span><span style="font-family:'Times New Roman'; font-size:11pt">of</span><span style="font-family:'Times New Roman'; font-size:11pt"> new antibiotics. These could include:</span></p><p style="margin:5pt 0pt 0pt 28.35pt; text-align:justify; text-indent:-28.35pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">a)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Changes to the </span><span style="font-family:'Times New Roman'; font-size:11pt">r</span><span style="font-family:'Times New Roman'; font-size:11pt">egulatory environment </span><span style="font-family:'Times New Roman'; font-size:11pt">- </span><span style="font-family:'Times New Roman'; font-size:11pt">reduc</span><span style="font-family:'Times New Roman'; font-size:11pt">ing</span><span style="font-family:'Times New Roman'; font-size:11pt"> the time interval from discovery to licensi</span><span style="font-family:'Times New Roman'; font-size:11pt">ng:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Using an approach comparable to cancer drugs, antibiotics for infections associated with high morbidity and mortality could be granted a restricted license based on Phase II trial data.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Bro</span><span style="font-family:'Times New Roman'; font-size:11pt">ader license</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> could</span><span style="font-family:'Times New Roman'; font-size:11pt"> be granted based on a finite number of studies in </span><span style="font-family:'Times New Roman'; font-size:11pt">one or two indications</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">if sufficiently supported by relevant PK/PD and </span><span style="font-family:'Times New Roman'; font-size:11pt">safety data. </span><span style="font-family:'Times New Roman'; font-size:11pt">P</span><span style="font-family:'Times New Roman'; font-size:11pt">harmaceutical compan</span><span style="font-family:'Times New Roman'; font-size:11pt">ies</span><span style="font-family:'Times New Roman'; font-size:11pt"> would </span><span style="font-family:'Times New Roman'; font-size:11pt">undertake</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">post-marketing</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">studies </span><span style="font-family:'Times New Roman'; font-size:11pt">providing</span><span style="font-family:'Times New Roman'; font-size:11pt"> additional outcome and safety data</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">enabl</span><span style="font-family:'Times New Roman'; font-size:11pt">ing</span><span style="font-family:'Times New Roman'; font-size:11pt"> regulatory authorities to modify the label as appropriate</span></li></ul><p style="margin:0pt 0pt 0pt 46.35pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">b)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Changes to a</span><span style="font-family:'Times New Roman'; font-size:11pt">ntibiotic</span><span style="font-family:'Times New Roman'; font-size:11pt"> pricing</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">to reflect their value compared with other treatments (e.g. cancer drugs)</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 5pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">c)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Changes </span><span style="font-family:'Times New Roman'; font-size:11pt">to</span><span style="font-family:'Times New Roman'; font-size:11pt"> the practice of automatically restricting new antibiotics </span><span style="font-family:'Times New Roman'; font-size:11pt">for</span><span style="font-family:'Times New Roman'; font-size:11pt"> salvage therapy. </span><span style="font-family:'Times New Roman'; font-size:11pt">The use of </span><span style="font-family:'Times New Roman'; font-size:11pt">new</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">antibiotics</span><span style="font-family:'Times New Roman'; font-size:11pt"> as</span><span style="font-family:'Times New Roman'; font-size:11pt"> first-line therapy </span><span style="font-family:'Times New Roman'; font-size:11pt">(</span><span style="font-family:'Times New Roman'; font-size:11pt">or earl</span><span style="font-family:'Times New Roman'; font-size:11pt">y</span><span style="font-family:'Times New Roman'; font-size:11pt"> in the treatment path</span><span style="font-family:'Times New Roman'; font-size:11pt">) for serious infections </span><span style="font-family:'Times New Roman'; font-size:11pt">such as those caused by MRSA </span><span style="font-family:'Times New Roman'; font-size:11pt">may</span><span style="font-family:'Times New Roman'; font-size:11pt"> reduce the risk of resistance and reduce healthcare associated costs</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">5</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">,</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">6</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">, </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">4.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What measures (including </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">behavioral</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Infection control </span><span style="font-family:'Times New Roman'; font-size:11pt">has played a critical role in</span><span style="font-family:'Times New Roman'; font-size:11pt"> managing </span><span style="font-family:'Times New Roman'; font-size:11pt">antibiotic resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> in clinical settings</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">G</span><span style="font-family:'Times New Roman'; font-size:11pt">overnment</span><span style="font-family:'Times New Roman'; font-size:11pt"> targets </span><span style="font-family:'Times New Roman'; font-size:11pt">have</span><span style="font-family:'Times New Roman'; font-size:11pt"> increas</span><span style="font-family:'Times New Roman'; font-size:11pt">ed</span><span style="font-family:'Times New Roman'; font-size:11pt"> accountability and awareness and redu</span><span style="font-family:'Times New Roman'; font-size:11pt">c</span><span style="font-family:'Times New Roman'; font-size:11pt">ed</span><span style="font-family:'Times New Roman'; font-size:11pt"> cases of MRSA and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">C</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">difficile</span><span style="font-family:'Times New Roman'; font-size:11pt"> across</span><span style="font-family:'Times New Roman'; font-size:11pt"> NHS Trusts.</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">However, </span><span style="font-family:'Times New Roman'; font-size:11pt">while highly successful, </span><span style="font-family:'Times New Roman'; font-size:11pt">the scope of the</span><span style="font-family:'Times New Roman'; font-size:11pt">se</span><span style="font-family:'Times New Roman'; font-size:11pt"> targets has been limited to a small number of pathogens and indications. Therefore, it is essential that</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">N</span><span style="font-family:'Times New Roman'; font-size:11pt">ational performance measures </span><span style="font-family:'Times New Roman'; font-size:11pt">should be reassessed to ensure that they are appropriately targeted</span><span style="font-family:'Times New Roman'; font-size:11pt"> and take into account the changing environment in te</span><span style="font-family:'Times New Roman'; font-size:11pt">rms of causative pathogens and infections where there is a high risk of antibiotic resistance.   </span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">While s</span><span style="font-family:'Times New Roman'; font-size:11pt">tewardship </span><span style="font-family:'Times New Roman'; font-size:11pt">plays a central role</span><span style="font-family:'Times New Roman'; font-size:11pt"> in </span><span style="font-family:'Times New Roman'; font-size:11pt">reducing the risk of antibiotic resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> and</span><span style="font-family:'Times New Roman'; font-size:11pt"> superinfections, there are areas where stewardship can be improved to achieve the desired outcomes. </span><span style="font-family:'Times New Roman'; font-size:11pt">While t</span><span style="font-family:'Times New Roman'; font-size:11pt">he current </span><span style="font-family:'Times New Roman'; font-size:11pt">slogan</span><span style="font-family:'Times New Roman'; font-size:11pt"> “the right drug, the right dose, at </span><span style="font-family:'Times New Roman'; font-size:11pt">the right time and the right duration”</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">provides a helpful illustration of what stewardship pro</span><span style="font-family:'Times New Roman'; font-size:11pt">grams </span><span style="font-family:'Times New Roman'; font-size:11pt">should look like, it does not include the measurement of outcomes. There is a clear need for all CCGs and hospital to have:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:5pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A programme of activities/interventions in place aimed at improving the use of antibiotic and the</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline"> </span><span style="font-family:'Times New Roman'; font-size:11pt">measurement of their success</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 5pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Audit and benchmarking of antibiotic use</span></li></ul><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The measurement of outcomes needs to be undertaken by the clinical teams and </span><span style="font-family:'Times New Roman'; font-size:11pt">through </span><span style="font-family:'Times New Roman'; font-size:11pt">engagement with national clinical groups </span><span style="font-family:'Times New Roman'; font-size:11pt">in specialties such as acute medicine, emergency medicine, orthopaedics, trauma and GPs.</span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Furthermore, t</span><span style="font-family:'Times New Roman'; font-size:11pt">he current stewardship initiatives </span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">do not</span><span style="font-family:'Times New Roman'; font-size:11pt"> address many fundamental issues associated with antibiotic resistance. To effectively address antibiotic resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> at a patient </span><span style="font-family:'Times New Roman'; font-size:11pt">level requires</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:5pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A</span><span style="font-family:'Times New Roman'; font-size:11pt"> greater understanding of pathogenesis</span><span style="font-family:'Times New Roman'; font-size:11pt"> and</span><span style="font-family:'Times New Roman'; font-size:11pt"> the contribution</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> of different interventions (e.g. antibiotics, surgery)</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Improved diagnostic techniques to target interventions more </span><span style="font-family:'Times New Roman'; font-size:11pt">effectively</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 5pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The need for a multi-disciplinary team approach to optimise patient outcomes in the management of complex inf</span><span style="font-family:'Times New Roman'; font-size:11pt">ections (e.g. infections associated with implanted prosthetic material/devices, endocarditis</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super"> 9</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">, 10</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ul><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Antibiotics are not “wonder drugs” </span><span style="font-family:'Times New Roman'; font-size:11pt">in the management of complex infections </span><span style="font-family:'Times New Roman'; font-size:11pt">but can achieve</span><span style="font-family:'Times New Roman'; font-size:11pt"> a remarkably high level of success</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">if the</span><span style="font-family:'Times New Roman'; font-size:11pt"> most effective antibi</span><span style="font-family:'Times New Roman'; font-size:11pt">otics</span><span style="font-family:'Times New Roman'; font-size:11pt"> are</span><span style="font-family:'Times New Roman'; font-size:11pt"> combined with the correct surgery and</span><span style="font-family:'Times New Roman'; font-size:11pt">/or</span><span style="font-family:'Times New Roman'; font-size:11pt"> source control of the infected site</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">7</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">, </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">8</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">There have been significant advances in diagnostic </span><span style="font-family:'Times New Roman'; font-size:11pt">techniques that should be employed to identify the causative pathogens and direct antibiotic treatment more </span><span style="font-family:'Times New Roman'; font-size:11pt">effectively</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">9</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">, 1</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">0</span><span style="font-family:'Times New Roman'; font-size:11pt">. The multidisciplinary team (MDT) approach is increasingly being seen as best practice in the treatment of complex infections such as </span><span style="font-family:'Times New Roman'; font-size:11pt">endocarditis, </span><span style="font-family:'Times New Roman'; font-size:11pt">prosthetic joint and vascular graft infection</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">7</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The education and training of healthcare professionals is critical to success in addressing antibiotic resistance to ensure they have </span><span style="font-family:'Times New Roman'; font-size:11pt">a good understanding of pathogenesis, antibiotic resistance </span><span style="font-family:'Times New Roman'; font-size:11pt">and best practices in the use of antibacterial drugs.    </span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Ther</span><span style="font-family:'Times New Roman'; font-size:11pt">e are potential deleterious consequences of a simplistic view of antibiotic stewardship, namely</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> restricting the newer and more expensive antibiotics in favour of </span><span style="font-family:'Times New Roman'; font-size:11pt">“cheaper” and generic antibiotics</span><span style="font-family:'Times New Roman'; font-size:11pt"> for “salvage” use. These consequences </span><span style="font-family:'Times New Roman'; font-size:11pt">can include </span><span style="font-family:'Times New Roman'; font-size:11pt">increasing the overall treatment course</span><span style="font-family:'Times New Roman'; font-size:11pt"> and associated risks for</span><span style="font-family:'Times New Roman'; font-size:11pt">, morbidity</span><span style="font-family:'Times New Roman'; font-size:11pt"> and mortality</span><span style="font-family:'Times New Roman'; font-size:11pt"> to the patient,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">selecting resistant mutants</span><span style="font-family:'Times New Roman'; font-size:11pt"> and increasing the overall healthcare associated costs.</span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">International programs such as the Surv</span><span style="font-family:'Times New Roman'; font-size:11pt">iv</span><span style="font-family:'Times New Roman'; font-size:11pt">ing Sepsis Campaign</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt"> adv</span><span style="font-family:'Times New Roman'; font-size:11pt">ocate giving the most potent and broad spectrum agent(s) as initial therapy in patients with suspected sepsis and then </span><span style="font-family:'Times New Roman'; font-size:11pt">d</span><span style="font-family:'Times New Roman'; font-size:11pt">e-escalating to </span><span style="font-family:'Times New Roman'; font-size:11pt">antimicrobials</span><span style="font-family:'Times New Roman'; font-size:11pt"> with a narrower spectrum</span><span style="font-family:'Times New Roman'; font-size:11pt"> (if appropriate), once </span><span style="font-family:'Times New Roman'; font-size:11pt">the underlying pathogen, resistance patterns, and the pat</span><span style="font-family:'Times New Roman'; font-size:11pt">ient’s res</span><span style="font-family:'Times New Roman'; font-size:11pt">ponse to treatment become clear.</span><span style="font-family:'Times New Roman'; font-size:11pt"> This approach has been shown to deliver better outcomes in these circumstances.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">5. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">-border initiatives?</span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Through the </span><span style="font-family:'Times New Roman'; font-size:11pt">activities of the British Society for Antimicrobial Chemotherapy (BSAC) and its initiative Antibiotic Action</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:11pt">the UK is at the vanguard of initiatives to address antibiotic resistance.</span><span style="font-family:'Times New Roman'; font-size:11pt"> This forum allows multiple stakeholders to identify, discuss and address key issues in the research, regulatory and </span><span style="font-family:'Times New Roman'; font-size:11pt">market</span><span style="font-family:'Times New Roman'; font-size:11pt"> environments, and </span><span style="font-family:'Times New Roman'; font-size:11pt">is</span><span style="font-family:'Times New Roman'; font-size:11pt"> regenerat</span><span style="font-family:'Times New Roman'; font-size:11pt">ing </span><span style="font-family:'Times New Roman'; font-size:11pt">interest in the discovery and development of new antibiotic agents.  </span></p><p style="margin:5pt 0pt"><span style="font-family:'Times New Roman'; font-size:11pt">U</span><span style="font-family:'Times New Roman'; font-size:11pt">nder the leadership and dir</span><span style="font-family:'Times New Roman'; font-size:11pt">ection of Professor Laura Piddock, </span><span style="font-family:'Times New Roman'; font-size:11pt">Antibiotic Action </span><span style="font-family:'Times New Roman'; font-size:11pt">has been highly proactive in reaching out to important</span><span style="font-family:'Times New Roman'; font-size:11pt"> individuals and organisations</span><span style="font-family:'Times New Roman'; font-size:11pt"> in the UK and internationally</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> to address the serious problem of antibiotic resistance</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:5pt 0pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">As a global pharmaceutical company, Novartis recognises the international dimension of the challenge of antibiotic resistance </span><span style="font-family:'Times New Roman'; font-size:11pt">and is greatly encourage by </span><span style="font-family:'Times New Roman'; font-size:11pt">the publication of the</span><span style="font-family:'Times New Roman'; font-size:11pt"> Government’s AMR </span><span style="font-family:'Times New Roman'; font-size:11pt">Strategy </span><span style="font-family:'Times New Roman'; font-size:11pt">and the impetus provided by the C</span><span style="font-family:'Times New Roman'; font-size:11pt">MO</span><span style="font-family:'Times New Roman'; font-size:11pt">’s interest in the</span><span style="font-family:'Times New Roman'; font-size:11pt"> subject. The UK </span><span style="font-family:'Times New Roman'; font-size:11pt">is </span><span style="font-family:'Times New Roman'; font-size:11pt">idea</span><span style="font-family:'Times New Roman'; font-size:11pt">l</span><span style="font-family:'Times New Roman'; font-size:11pt">l</span><span style="font-family:'Times New Roman'; font-size:11pt">y</span><span style="font-family:'Times New Roman'; font-size:11pt"> position</span><span style="font-family:'Times New Roman'; font-size:11pt">ed</span><span style="font-family:'Times New Roman'; font-size:11pt"> to assume a leading role in tackling the global threat of antimicrobial resistance. </span><span style="font-family:'Times New Roman'; font-size:11pt">However, a</span><span style="font-family:'Times New Roman'; font-size:11pt">ny changes implemented in the UK will need to be adopted internationally to maximize their impact and for progress to be ma</span><span style="font-family:'Times New Roman'; font-size:11pt">de. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 5pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">6. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?</span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The Government’s five ye</span><span style="font-family:'Times New Roman'; font-size:11pt">ar</span><span style="font-family:'Times New Roman'; font-size:11pt"> AMR</span><span style="font-family:'Times New Roman'; font-size:11pt"> Strategy </span><span style="font-family:'Times New Roman'; font-size:11pt">provides</span><span style="font-family:'Times New Roman'; font-size:11pt"> a useful platform to start</span><span style="font-family:'Times New Roman'; font-size:11pt"> addressing some key issues in the area of antimicrobial resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt">is generally balanced in its assessment of</span><span style="font-family:'Times New Roman'; font-size:11pt"> the challenge</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">If delivered, t</span><span style="font-family:'Times New Roman'; font-size:11pt">he three strategic aims would go a significant way to address</span><span style="font-family:'Times New Roman'; font-size:11pt">ing</span><span style="font-family:'Times New Roman'; font-size:11pt"> the considerable c</span><span style="font-family:'Times New Roman'; font-size:11pt">hallenges presented by antibiotic resistance</span><span style="font-family:'Times New Roman'; font-size:11pt">. Novartis were pleased to note that antibiotic stewardship (subject to the caveats presented in the document above), the urgent need for the discovery and developments of new antibiotics, diagnostics and novel t</span><span style="font-family:'Times New Roman'; font-size:11pt">herapies and approaches are core themes within the strategy. </span><span style="font-family:'Times New Roman'; font-size:11pt">The Strategy recognises the importance of improving knowledge amongst healthcare professionals and the </span><span style="font-family:'Times New Roman'; font-size:11pt">general public to try and ensure that current treatment are preserved and used appropriately</span><span style="font-family:'Times New Roman'; font-size:11pt">. These statements and objectives need to go further to include the recognition that education and training of healthcare professionals </span><span style="font-family:'Times New Roman'; font-size:11pt">to gain a far greater understanding of pathogenesis. Moreover, the importance of changes in current practice to enhance </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt">develop the</span><span style="font-family:'Times New Roman'; font-size:11pt"> role of multidisciplinary teams in managing complex infections needs to be included. </span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">he Strategy</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">places</span><span style="font-family:'Times New Roman'; font-size:11pt"> s</span><span style="font-family:'Times New Roman'; font-size:11pt">ignificant obligations on industry to produce new treatments</span><span style="font-family:'Times New Roman'; font-size:11pt"> but w</span><span style="font-family:'Times New Roman'; font-size:11pt">ithout offering re</span><span style="font-family:'Times New Roman'; font-size:11pt">ciprocal commitments</span><span style="font-family:'Times New Roman'; font-size:11pt"> to improving the </span><span style="font-family:'Times New Roman'; font-size:11pt">restrictive</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">commercial environment</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">  </span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">he Government must make concrete commitments to how they plan to </span><span style="font-family:'Times New Roman'; font-size:11pt">analyse</span><span style="font-family:'Times New Roman'; font-size:11pt"> the challenges </span><span style="font-family:'Times New Roman'; font-size:11pt">associated with AMR further and translate these, in collaboration with stakeholders, into initiatives that will drive real change.  In addre</span><span style="font-family:'Times New Roman'; font-size:11pt">ssing the commercial environment, </span><span style="font-family:'Times New Roman'; font-size:11pt">the High Level Steering Group must outline how it plans to address some of the key challenges which it started to identify in the Strategy.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The Strategy recommends a substantial and extended research program to </span><span style="font-family:'Times New Roman'; font-size:11pt">better und</span><span style="font-family:'Times New Roman'; font-size:11pt">erstand resistance, discover new therapies and improve surveillance of antibiotic resistance. This will clearly need new and substantial funding. With reference to the concerns about the significant obligation on </span><span style="font-family:'Times New Roman'; font-size:11pt">industry inferred</span><span style="font-family:'Times New Roman'; font-size:11pt"> in the Strategy, will new central (Government) funding be made available?</span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Focus on</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold"> Vaccines </span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 13.25pt; padding-left:0.95pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Introduction:</span><span style="font-family:'Times New Roman'; font-size:11pt"> The role of vaccines in keeping antibiotic usage in check is widely acknowledged and a number of vaccines against nosocomial pathogens are under development. However, the likelihood that such vaccines will be developed for the UK population is extremely l</span><span style="font-family:'Times New Roman'; font-size:11pt">ow due to the following reasons:</span></li><ol type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 27.45pt; padding-left:8pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Failure of the JCVI to endorse the serogroup B meningococcal vaccine:</span><span style="font-family:'Times New Roman'; font-size:11pt"> After around 20 years of development, this vaccine was licensed in the European Union at the beginning of 2013. However, despite there being a high burde</span><span style="font-family:'Times New Roman'; font-size:11pt">n of serogroup B meningococcal disease in the UK, the JCVI failed to endorse the vaccine at its June 2013 committee meeting</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">13</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">This does not auger well for future vaccines against severe life-threatening infections.</span></li></ol></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 42.55pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 28.07pt; padding-left:7.38pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Failure of House of Lords meeting 9</span><span style="font-family:'Times New Roman'; font-size:7.33pt; font-weight:bold; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> March 2010 to endorse vaccines against nosocomial pathogens and suggestion that vaccines against nosocomial pathogens could actually </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">increase</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> antibiotic usage:</span><span style="font-family:'Times New Roman'; font-size:11pt"> At a House of Lords meeting on 9</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt"> March 2010 chaired by The Lord Toby Harris, it was maintaine</span><span style="font-family:'Times New Roman'; font-size:11pt">d that far from decreasing antibiotic usage, the deployment of vaccines against nosocomial pathogens would </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">increase</span><span style="font-family:'Times New Roman'; font-size:11pt"> antibiotic usage by promoting complacency amongst medical practitioners. The meeting failed to endorse the development of such vaccines</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol></ol><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 0pt 72pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 26.83pt; padding-left:8.62pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Fa</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ilure of the UK Five Year Antimicrobial Resistance Strategy 2013 to 2018 explicitly to acknowledge that vaccines have played a role in reducing antibiotic resistance since 2000:</span><span style="font-family:'Times New Roman'; font-size:11pt"> Whilst the UK strategy document</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">14</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super"> </span><span style="font-family:'Times New Roman'; font-size:11pt">acknowledges the need for new vaccines again</span><span style="font-family:'Times New Roman'; font-size:11pt">st multi-resistant pathogens, at no point does the document acknowledge that vaccines may have played </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">any</span><span style="font-family:'Times New Roman'; font-size:11pt"> role in reducing antibiotic resistance since 2000.</span></li></ol></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 42.55pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 13.25pt; padding-left:0.95pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Differences between antibiotics and vaccines</span></li><ol type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 10pt 27.45pt; padding-left:8pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">he following table outlines some major differences b</span><span style="font-family:'Times New Roman'; font-size:11pt">etween antibiotics and vaccines</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">15</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span></li></ol></ol><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:42.55pt"><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Relevant Feature</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Antibiotics</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Vaccines</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Therapeutic/prophylactic</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Mostly therapeutic</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Mostly prophylactic</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Coverage and specificity</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Broad, indiscriminate</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Narrow, specific</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Emergence of resistance</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Common</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Uncommon</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Selective </span><span style="font-family:'Times New Roman'; font-size:11pt">pressure</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">High</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Low</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Time to develop resistance</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Short</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Long</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Durability</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Restricted to the time of treatment</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Duration of protection persists from several months up to life-long</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Duration/frequency of exposure</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Some patients spend weeks/months on antibiotics, </span><span style="font-family:'Times New Roman'; font-size:11pt">with the potential for prolonged sub-therapeutic exposure</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Sub-optimal schedules or responses can lead to breakthrough infections</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Cross-class impact</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Potential for a single antibiotic to drive plasmid-mediated resistance to multiple antibiotics across diffe</span><span style="font-family:'Times New Roman'; font-size:11pt">rent classes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Impact of the vaccine is generally restricted to a particular type of organism, although removal of nasopharyngeal carriage can allow other types of organisms to occupy the niche</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Beneficial herd effect</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">No</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Yes</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Prevention of perinatal infectio</span><span style="font-family:'Times New Roman'; font-size:11pt">ns</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Yes</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Yes (maternal immunisation)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Prevention of cancer</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">No</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Yes (HBV, HPV)</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Control of distribution</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Less tightly controlled and monitored distribution (prescribed across the breadth of the health system with variable scrutiny, control and guideline </span><span style="font-family:'Times New Roman'; font-size:11pt">adherence</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Generally distributed through the immunisation programme, and the impact closely monitored</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:163pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Cost</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:106.3pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Few ₤s to ₤1000s</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:141.75pt"><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Few ₤s to ₤100s</span></p></td></tr></table><p style="font-size:8pt; line-height:108%; margin:0pt 0pt 0pt 72pt; text-indent:-29.45pt"><span style="font-family:'Times New Roman'; font-size:8pt">Adapted from</span><span style="font-family:'Times New Roman'; font-size:8pt"> Mishra </span><span style="font-family:'Times New Roman'; font-size:8pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:8pt"> </span><span style="font-family:'Times New Roman'; font-size:5.33pt; vertical-align:super">15</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 0pt 72pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 28.07pt; padding-left:7.38pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Antibiotic prophylaxis: </span><span style="font-family:'Times New Roman'; font-size:11pt">The prophylactic use of antibiotics is common practice, for </span><span style="font-family:'Times New Roman'; font-size:11pt">example in surgical procedures including trauma patients, routine ‘clean’ surgical wounds, dental surgery, neutropenia, some malignant neoplasias, after chemotherapy, and in pregnant women to prevent perinatal infections. Unfortunately, the intense use of </span><span style="font-family:'Times New Roman'; font-size:11pt">antibiotics in these settings has substantially contributed to the emergence of resistant strains and also to the reduced efficacy of antibiotics.</span></li></ol></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 26.83pt; padding-left:8.62pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">The use of vaccines to reduce antibiotic resistance:</span><span style="font-family:'Times New Roman'; font-size:11pt"> Vaccines are a key component in the fight against antib</span><span style="font-family:'Times New Roman'; font-size:11pt">iotic resistance, both directly and indirectly. By targeting bacterial pathogens, </span><span style="font-family:'Times New Roman'; font-size:11pt">vaccines </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">directly</span><span style="font-family:'Times New Roman'; font-size:11pt"> reduce the need for the use of antibiotics. Vaccines can also have an </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">indirect</span><span style="font-family:'Times New Roman'; font-size:11pt"> benefit, for example, in preventing viral infections such as influenza, measl</span><span style="font-family:'Times New Roman'; font-size:11pt">es and varicella and thereby the secondary bacterial </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">super-infections</span><span style="font-family:'Times New Roman'; font-size:11pt"> associated with these viral infections.</span></li></ol></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="a" style="margin:0pt; padding-left:0pt"><ol start="4" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 28.07pt; padding-left:7.38pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Vaccines and herd protection:</span><span style="font-family:'Times New Roman'; font-size:11pt"> Vaccines also contribute to the reduction in antibiotic use through the establishment of herd protection.</span></li></ol></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 13.25pt; padding-left:0.95pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Role of meningococcal, pneumococcal and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Haemophilus influenzae</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> type b vaccines</span></li><ol type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 27.45pt; padding-left:8pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">After the introduction of </span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">serogroup C meningococcal conjugate vaccine</span><span style="font-family:'Times New Roman'; font-size:11pt"> in the UK in 1999, there was an immediate and dramatic impact on the number of cases of diseases (and there</span><span style="font-family:'Times New Roman'; font-size:11pt">fore on the number of courses of antibiotics). For invasive meningococcal disease, the early impact of the serogroup C meningococcal conjugate vaccine was described as follows: “A total of 836 cases of meningococcal disease were identified through the enha</span><span style="font-family:'Times New Roman'; font-size:11pt">nced surveillance system in the eight English regions, Wales and Northern Ireland during the fourth quarter of 2000, 32% lower than in the equivalent quarter in 1999 (1238)”</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">16</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 10pt 28.07pt; padding-left:7.38pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Longer-term impact of serogroup C meningococcal conjugate vaccine in the UK</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">17</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span></li></ol></ol><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Century Gothic'; font-size:11pt">&#xa0;</span><img src="data:image/png;base64,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" width="549" height="400" alt="" style="margin-left:33.75pt; margin-top:1.85pt; position:absolute; z-index:0" /></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 35.45pt"><span style="font-family:'Times New Roman'; font-size:11pt">This represents a 93% reduction in the incidence of invasive serogroup C disease over the first 4 years after the introduction of the vaccine</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">17</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt"><br style="page-break-before:always; clear:both" /></p><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 10pt 33.93pt; padding-left:8.62pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">When taken in combination, the impact of meningococcal, pneumococcal and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Haemophilus </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">influenzae</span><span style="font-family:'Times New Roman'; font-size:11pt"> typ</span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt"> b vaccines on disease incidence in the UK has been considerable:</span></li></ol></ol><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt"><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:147.15pt"><p style="margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:42.55pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1992</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:42.5pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1996/1997</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:52.3pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1998/ 1999</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:60.15pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2004/ 2005</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.9pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2010</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.1pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2011/ 2012</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:50.45pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2012</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:147.15pt"><p style="margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:11pt">Hib meningitis</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">18</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:42.55pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">871</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:42.5pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:52.3pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:60.15pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.9pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">30</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.1pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:50.45pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:147.15pt"><p style="margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:11pt">Pneumococcal meningitis</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">18,19</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:42.55pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:42.5pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">398*</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:52.3pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:60.15pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">252*</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.9pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.1pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&lt;100**</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:50.45pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td></tr><tr style="height:33.8pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:147.15pt"><p style="margin:0pt 0pt 10pt"><span style="font-family:'Times New Roman'; font-size:11pt">Meningococcal </span><span style="font-family:'Times New Roman'; font-size:11pt">disease</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">20</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">(meningitis and septicaemia) </span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:42.55pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:42.5pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:52.3pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2773</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:60.15pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:34.9pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="background-color:#d0cece; border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:51.1pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:50.45pt"><p style="margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">766</span></p></td></tr></table><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 72pt; text-indent:-33.3pt"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 42.55pt"><span style="font-family:'Times New Roman'; font-size:11pt">In the USA, a </span><span style="font-family:'Times New Roman'; font-size:11pt">decrease in 87% in antibiotic resistant disease caused by vaccine serotypes</span><span style="font-family:'Times New Roman'; font-size:11pt"> was reported </span><span style="font-family:'Times New Roman'; font-size:11pt">after the introduction of the pneumococcal conjugate vaccine</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">21 </span></p><ol start="4" type="a" style="margin:0pt; padding-left:0pt"><ol start="4" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 35.17pt; padding-left:7.38pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">These statistics represent not only </span><span style="font-family:'Times New Roman'; font-size:11pt">considerable reductions in courses of antibiotics for serious invasive disease but also considerable reductions in hospitalisations.</span></li></ol></ol><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 0pt 72pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 0pt 13.25pt; padding-left:8.05pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Potential of vaccines for changing clinical practice</span><span style="font-family:'Times New Roman'; font-size:11pt">: With the potential for the introduction of a serogroup B </span><span style="font-family:'Times New Roman'; font-size:11pt">meningococcal vaccine, there is also the potential to reduce serious invasive bacterial meningitis and septicaemia to historically low levels. This is likely to lead to changes in clinical practice: the number of septic workups performed, the number of hos</span><span style="font-family:'Times New Roman'; font-size:11pt">pitalisations, the number of courses of antibiotics, and on antibiotic resistance.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:0pt 0pt 10pt 13.25pt; padding-left:8.05pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Role of influenza vaccines</span><span style="font-family:'Times New Roman'; font-size:11pt">: There is some evidence that influenza vaccines play a role in reducing antibiotic </span><span style="font-family:'Times New Roman'; font-size:11pt">usage and </span><span style="font-family:'Times New Roman'; font-size:11pt">resistance</span><span style="font-family:'Times New Roman'; font-size:11pt"> by reduc</span><span style="font-family:'Times New Roman'; font-size:11pt">ing </span><span style="font-family:'Times New Roman'; font-size:11pt">bacterial infection in </span><span style="font-family:'Times New Roman'; font-size:11pt">vaccinated individuals and the infants</span><span style="font-family:'Times New Roman'; font-size:11pt"> of women vaccinated in pregnancy</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">22, 23, 24</span></li></ol><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">References</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:5pt 0pt 0pt 13.25pt; padding-left:8pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Hawkey PM and Jones AM. The changing epidemiology of resistance. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Journal of Antimicrobial Chemotherapy</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2009</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">64 </span><span style="font-family:'Times New Roman'; font-size:11pt">(</span><span style="font-family:'Times New Roman'; font-size:11pt">S1</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">: </span><span style="font-family:'Times New Roman'; font-size:11pt">i3-i10.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:8pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Mossialos </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> (2009) </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Policies and incentives for promoting innovation in antibiotic research, </span><span style="font-family:'Times New Roman'; font-size:11pt">available here: http://www.euro.who.int/__data/assets/pdf_file/0011/120143/E94241.pdf, p11.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:8pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Theuretzbacher U. Accelerating resistance, inadequate antibacterial drug pipelines and inte</span><span style="font-family:'Times New Roman'; font-size:11pt">rnational responses. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">International Journal of Antimicr</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">o</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">bial Agents</span><span style="font-family:'Times New Roman'; font-size:11pt">, 2012, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">39</span><span style="font-family:'Times New Roman'; font-size:11pt">, 295-299.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 5pt 13.25pt; padding-left:8pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Public Health England Mandatory Bacteraemia Surveillance:  http://www.hpa.org.uk/web/HPAweb&amp;Page&amp;HPAwebAutoListName/Page/1191942169773</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:5pt 0pt 0pt 13.25pt; padding-left:8pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">Gould IM. Is vancomyin redundant for serious staphylococcal infection? </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; text-decoration:none">International Journal of Antimicrobial Agents, </span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">2009</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">;</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">36S</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">:</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none"> S55-S57</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:8pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">Patel N </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; text-decoration:none">et al</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">. Vancomycin: We can get there from </span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">h</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">ere. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; text-decoration:none">Clinical infectious Diseases</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">, 2011</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">;</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:none">52</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">: </span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:none">969-974 </span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:8pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Chambers J </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et a</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">l</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">(</span><span style="font-family:'Times New Roman'; font-size:11pt">2013</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> The infective endocarditis team: recommendations from and international working group. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Heart</span><span style="font-family:'Times New Roman'; font-size:11pt"> (published online): http://heart.bmj.com/content/early/2013/08/29/heartjnl-2013-304354.full.html</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:8pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Zimmerli W and Trampuz A</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Current Concepts; Prosthetic Joint Infections. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">NEJM</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">2004</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">351</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">1645-1654.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.25pt; padding-left:8pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Corvec S </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Epidemiology and new developments in the diagnosis of prosthetic joint infection. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">International Journal of Artificial Organs, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">2012</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">10</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">923-934.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:2.5pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Cazanave C </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Ra</span><span style="font-family:'Times New Roman'; font-size:11pt">pid molecular microbiologic diagnosis of prosthetic joint infection. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Journal of Clinical Microbiology, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">2013</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">51</span><span style="font-family:'Times New Roman'; font-size:11pt">:</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">2280-2287.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 5pt 18.75pt; padding-left:2.5pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">http://www.survivingsepsis.org</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:5pt 0pt 0pt 18.75pt; padding-left:2.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">http://antibiotic-action.com</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:2.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">https://www.gov.uk/government/policy-advisory-groups/joint-committee-on-vaccination-and-immunisation#minutes</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:2.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:2.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Mishra </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. Vaccines and ant</span><span style="font-family:'Times New Roman'; font-size:11pt">ibiotic resistance. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Current Opinion in Microbiology</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2012; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">15</span><span style="font-family:'Times New Roman'; font-size:11pt"> (5): 596–602.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:2.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">http://webarchive.nationalarchives.gov.uk/+/http://www.hpa.org.uk/cdr/archives/2001/cdr0801.pdf</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:2.5pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Gray SJ, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J Med Microbiol</span><span style="font-family:'Times New Roman'; font-size:11pt">. 2006;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">55</span><span style="font-family:'Times New Roman'; font-size:11pt">:887-896</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:108%; margin:0pt 0pt 0pt 18.75pt; padding-left:2.55pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HaemophilusInfluenzaeTypeB/EpidemiologicalData/haem_DataLabAgeQtr/</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:2.55pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">http://www.hpa.org.uk/web/HPAweb&amp;Page&amp;HPAwebAutoListDate/Page/1281953376223</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:2.55pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">http://www.hpa.org.uk/Topics/InfectiousDiseases/Infe</span><span style="font-family:'Times New Roman'; font-size:11pt">ctionsAZ/MeningococcalDisease/EpidemiologicalData/</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 18.75pt; padding-left:2.55pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Kyaw </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-Resistant Streptococcus </span><span style="font-family:'Times New Roman'; font-size:11pt">pneumoniae. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">N</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ew England Journal of Medicine</span><span style="font-family:'Times New Roman'; font-size:11pt">, 2006; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">354</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">:</span><span style="font-family:'Times New Roman'; font-size:11pt">1455-1463</span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:108%; margin:0pt 0pt 0pt 18.75pt; padding-left:2.55pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Block </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">The Efficacy of Live </span><span style="font-family:'Times New Roman'; font-size:11pt">Attenuated Influenza Vaccine Against Influenza-associated Acute Otitis Media in Children</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">P</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">aediatric </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">I</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">nfectious </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">D</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">isease </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">J</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ournal,</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2011; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">30</span><span style="font-family:'Times New Roman'; font-size:11pt">: 203-207</span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:108%; margin:0pt 0pt 0pt 18.75pt; padding-left:2.55pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Zaman </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Effectiveness of Maternal Influenza Immunization in Mothers and Infants</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">N</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ew England Journal of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Medicine</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2008; </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">358</span><span style="font-family:'Times New Roman'; font-size:11pt">: 1555-1564</span></li><li style="font-family:'Times New Roman'; font-size:11pt; line-height:108%; margin:0pt 0pt 8pt 18.75pt; padding-left:2.55pt; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Hartshorn</span><span style="font-family:'Times New Roman'; font-size:11pt"> KL</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">New Look at an Old Problem</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Bacterial S</span><span style="font-family:'Times New Roman'; font-size:11pt">uperinfection after Influenza</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Am</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">erican</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> J</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ournal of</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> Pathol</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ogy</span><span style="font-family:'Times New Roman'; font-size:11pt">, 2010</span><span style="font-family:'Times New Roman'; font-size:11pt">;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">176</span><span style="font-family:'Times New Roman'; font-size:11pt">(2): 536-539. </span></li></ol><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 8pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">October 2013</span><br style="page-break-before:always; clear:both" /></p><p style="font-size:11pt; line-height:108%; margin:0pt 0pt 0pt 21.3pt; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Declaration of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">authors’ </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">interests</span></p><p style="font-size:11pt; line-height:108%; margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">E. David G. McIntosh</span><span style="font-family:'Times New Roman'; font-size:11pt"> is an employee of Novartis Vaccines, a manufacturer of vaccines</span><span style="font-family:'Times New Roman'; font-size:11pt"> for the prevention of bacterial infection</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:108%; margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Mike Allen is an employee</span><span style="font-family:'Times New Roman'; font-size:11pt"> of Novartis Pharmaceuticals UK Ltd, a subsidiary of Novartis AG, </span><span style="font-family:'Times New Roman'; font-size:11pt">a company that</span><span style="font-family:'Times New Roman'; font-size:11pt"> develop</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> and market</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt"> antibiotics.</span></p><p style="margin:0pt 0pt 6pt 21.3pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Century Gothic'; font-size:11pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:'Century Gothic'; font-size:9pt">&#xa0;</span></p></body></html>